IOBT
Price
$0.84
Change
+$0.03 (+3.70%)
Updated
Jan 17 closing price
Capitalization
55.12M
68 days until earnings call
YMAB
Price
$6.16
Change
-$0.02 (-0.32%)
Updated
Jan 17 closing price
Capitalization
275.9M
32 days until earnings call
Ad is loading...

IOBT vs YMAB

Header iconIOBT vs YMAB Comparison
Open Charts IOBT vs YMABBanner chart's image
IO Biotech
Price$0.84
Change+$0.03 (+3.70%)
Volume$127.04K
Capitalization55.12M
Y-mAbs Therapeutics
Price$6.16
Change-$0.02 (-0.32%)
Volume$325.81K
Capitalization275.9M
IOBT vs YMAB Comparison Chart
Loading...
IOBT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IOBT vs. YMAB commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IOBT is a Hold and YMAB is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (IOBT: $0.84 vs. YMAB: $6.16)
Brand notoriety: IOBT and YMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IOBT: 31% vs. YMAB: 94%
Market capitalization -- IOBT: $55.12M vs. YMAB: $275.9M
IOBT [@Biotechnology] is valued at $55.12M. YMAB’s [@Biotechnology] market capitalization is $275.9M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IOBT’s FA Score shows that 1 FA rating(s) are green whileYMAB’s FA Score has 0 green FA rating(s).

  • IOBT’s FA Score: 1 green, 4 red.
  • YMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, IOBT is a better buy in the long-term than YMAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IOBT’s TA Score shows that 2 TA indicator(s) are bullish while YMAB’s TA Score has 5 bullish TA indicator(s).

  • IOBT’s TA Score: 2 bullish, 5 bearish.
  • YMAB’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, YMAB is a better buy in the short-term than IOBT.

Price Growth

IOBT (@Biotechnology) experienced а -3.95% price change this week, while YMAB (@Biotechnology) price change was -10.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

IOBT is expected to report earnings on May 19, 2025.

YMAB is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
YMAB($276M) has a higher market cap than IOBT($55.1M). IOBT YTD gains are higher at: -9.065 vs. YMAB (-21.328). YMAB has higher annual earnings (EBITDA): -27.87M vs. IOBT (-89.37M). IOBT has more cash in the bank: 80.2M vs. YMAB (68.1M). YMAB has less debt than IOBT: YMAB (1.08M) vs IOBT (2.02M). YMAB has higher revenues than IOBT: YMAB (84.6M) vs IOBT (0).
IOBTYMABIOBT / YMAB
Capitalization55.1M276M20%
EBITDA-89.37M-27.87M321%
Gain YTD-9.065-21.32843%
P/E RatioN/AN/A-
Revenue084.6M-
Total Cash80.2M68.1M118%
Total Debt2.02M1.08M188%
FUNDAMENTALS RATINGS
YMAB: Fundamental Ratings
YMAB
OUTLOOK RATING
1..100
52
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
95
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
IOBTYMAB
RSI
ODDS (%)
N/A
Bullish Trend 11 days ago
72%
Stochastic
ODDS (%)
Bearish Trend 11 days ago
86%
Bullish Trend 11 days ago
82%
Momentum
ODDS (%)
Bearish Trend 11 days ago
90%
N/A
MACD
ODDS (%)
N/A
Bullish Trend 11 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
85%
Bearish Trend 11 days ago
87%
Advances
ODDS (%)
Bullish Trend 16 days ago
90%
Bullish Trend 16 days ago
81%
Declines
ODDS (%)
Bearish Trend 19 days ago
90%
Bearish Trend 11 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
90%
Bullish Trend 11 days ago
82%
Aroon
ODDS (%)
Bullish Trend 11 days ago
85%
Bearish Trend 11 days ago
87%
View a ticker or compare two or three
Ad is loading...
IOBT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OVID0.740.01
+1.37%
Ovid Therapeutics
BLCO17.36-0.08
-0.46%
Bausch + Lomb Corp
GCI4.98-0.03
-0.60%
Gannett Co
DAC77.46-0.49
-0.63%
Danaos Corp
MCO475.85-3.15
-0.66%
Moody's Corp

IOBT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IOBT has been loosely correlated with GLMD. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if IOBT jumps, then GLMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IOBT
1D Price
Change %
IOBT100%
+3.41%
GLMD - IOBT
38%
Loosely correlated
-1.02%
RCKT - IOBT
35%
Loosely correlated
+0.98%
YMAB - IOBT
32%
Poorly correlated
-0.32%
RXRX - IOBT
31%
Poorly correlated
+2.03%
TRDA - IOBT
30%
Poorly correlated
+1.20%
More